High-density sub-100-nm peptide-gold nanoparticle complexes improve vaccine presentation by dendritic cells in vitro

Nanoscale Research Letters

Volumn 8, Issue 1, 2013, Pages 1-11

  Lin, Adam Yuh ^a   Lunsford, Jessica ^b   Bear, Adham Sean ^b   Young, Joseph Keith ^a   Eckels, Phillip ^b   Luo, Laureen ^a   Foster, Aaron Edward ^b   Drezek, Rebekah Anna ^a  

^a Rice University   (United States)

^b CENTER FOR CELL AND GENE THERAPY   (United States)

Author keywords

Dendritic cells; ELISPOTs; Gold nanoparticles; Immunotherapy; Self assembled monolayer; Vaccines

Indexed keywords

ANTIGENS; CELLS; FIBER OPTIC SENSORS; GOLD COMPOUNDS; METAL NANOPARTICLES; PEPTIDES; SELF ASSEMBLED MONOLAYERS; TOXICITY; VACCINES;

CYTOTOXIC T LYMPHOCYTES; DENDRITIC CELLS; DENDRITIC CELLS (DCS); ELISPOTS; IMMUNE RESPONSE; IMMUNOTHERAPY; INTERFERON-GAMMA; SELF-ASSEMBLING;

GOLD NANOPARTICLES;

EID: 84875132710     PISSN: 19317573     EISSN: 1556276X     Source Type: Journal    
DOI: 10.1186/1556-276X-8-72     Document Type: Article

References (31)

1. Schlom J, Arlen PM, Gulley JL: Cancer vaccines: moving beyond current paradigms. Clin Cancer Res 2007, 13:3776-3782.
2. Rosenberg SA, Yang JC, Restifo NP: Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004, 10:909-915.
3. Pejawar-Gaddy S, Finn OJ: Cancer vaccines: accomplishments and challenges. Crit Rev Oncol Hematol 2008, 67:93-102.
4. Palucka K, Ueno H, Banchereau J: Recent developments in cancer vaccines. J Immunol 2011, 186:1325-1331.
5. Kawakami Y, Eliyahu S, Jennings C, Sakaguchi K, Kang X, Southwood S, Robbins PF, Sette A, Appella E, Rosenberg SA: Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. J Immunol 1995, 154:3961-3968.
6. Slingluff CL, Yamshchikov G, Neese P, Galavotti H, Eastham S, Engelhard VH, Kittlesen D, Deacon D, Hibbitts S, Grosh WW, Petroni G, Cohen R, Wiernasz C, Patterson JW, Conway BP, Ross WG: Phase I trial of a melanoma vaccine with gp100(280-288) peptide and tetanus helper peptide in adjuvant: immunologic and clinical outcomes. Clin Cancer Res 2001, 7:3012-3024.
7. Schwartzentruber D, Lawson D, Richards J, Conry R, Miller D, Triesman J, Gailani F, Riley L, Vena D, Hwu P: A phase III multi-institutional randomized study of immunization with the gp, 100: 209-217 (210 M) peptide followed by high-dose IL-2 compared with high-dose IL-2 alone in patients with metastatic melanoma. J Clin Oncol 2009, 27:209-211.
8. Krishnamachari Y, Geary SM, Lemke CD, Salem AK: Nanoparticle delivery systems in cancer vaccines. Pharm Res 2011, 28:215-236.
9. Reddy ST, Rehor A, Schmoekel HG, Hubbell JA, Swartz MA: In vivo targeting of dendritic cells in lymph nodes with poly(propylene sulfide) nanoparticles. J Control Release 2006, 112:26-34.
10. Reddy ST, van der Vlies AJ, Simeoni E, Angeli V, Randolph GJ, O'Neil CP, Lee LK, Swartz MA, Hubbell JA: Exploiting lymphatic transport and complement activation in nanoparticle vaccines. Nat Biotechnol 2007, 25:1159-1164.
11. Bastús NG, Sánchez-Tilló E, Pujals S, Farrera C, Kogan MJ, Giralt E, Celada A, Lloberas J, Puntes V: Peptides conjugated to gold nanoparticles induce macrophage activation. Mol Immunol 2009, 46:743-748.
12. Villiers C, Freitas H, Couderc R, Villiers M-B, Marche P: Analysis of the toxicity of gold nano particles on the immune system: effect on dendritic cell functions. J Nanopart Res 2010, 12:55-60.
13. Arnáiz B, Martínez-Ávila O, Falcon-Perez JM, Penadés S: Cellular uptake of gold nanoparticles bearing HIV gp120 oligomannosides. Bioconjug Chem 2012, 23:814-825.
14. Kennedy LC, Bear AS, Young JK, Lewinski NA, Kim J, Foster AE, Drezek RA: T cells enhance gold nanoparticle delivery to tumors in vivo. Nanoscale Res Lett 2011, 6:283.
15. Zhang G, Yang Z, Lu W, Zhang R, Huang Q, Tian M, Li L, Liang D, Li C: Influence of anchoring ligands and particle size on the colloidal stability and in vivo biodistribution of polyethylene glycol-coated gold nanoparticles in tumor-xenografted mice. Biomaterials 2009, 30:1928-1936.
16. Saleem IY, Vordermeier M, Barralet JE, Coombes AGA: Improving peptidebased assays to differentiate between vaccination and Mycobacterium bovis infection in cattle using nanoparticle carriers for adsorbed antigens. J Control Release 2005, 102:551-561.
17. Ojeda R, de Paz JL, Barrientos AG, Martín-Lomas M, Penadés S: Preparation of multifunctional glyconanoparticles as a platform for potential carbohydrate-based anticancer vaccines. Carbohydr Res 2007, 342:448-459.
18. Kim H-D, Maxwell JA, Kong F-K, Tang DC, Fukuchi K: Induction of antiinflammatory immune response by an adenovirus vector encoding 11 tandem repeats of Abeta1-6: toward safer and effective vaccines against Alzheimer's disease. Biochem Biophys Res Commun 2005, 336:84-92.
19. Yankai Z, Rong Y, Yi H, Wentao L, Rongyue C, Ming Y, Taiming L, Jingjing L, Jie W: Ten tandem repeats of beta-hCG 109-118 enhance immunogenicity and anti-tumor effects of beta-hCG C-terminal peptide carried by mycobacterial heat-shock protein HSP65. Biochem Biophys Res Commun 2006, 345:1365-1371.
20. Bergen JM, von Recum HA, Goodman TT, Massey AP, Pun SH: Gold nanoparticles as a versatile platform for optimizing physicochemical parameters for targeted drug delivery. Macromol Biosci 2006, 6:506-516.
21. Grabarek Z, Gergely J: Zero-length crosslinking procedure with the use of active esters. Anal Biochem 1990, 185:131-135.
22. Overwijk WW, Tsung A, Irvine KR, Parkhurst MR, Goletz TJ, Tsung K, Carroll MW, Liu C, Moss B, Rosenberg SA, Restifo NP: gp100/pmel 17 is a murine tumor rejection antigen: induction of "self"-reactive, tumoricidal T cells using high-affinity, altered peptide ligand. J Exp Med 1998, 188:277-286.
23. Mansour M, Pohajdak B, Kast WM, Fuentes-Ortega A, Korets-Smith E, Weir GM, Brown RG, Daftarian P: Therapy of established B16-F10 melanoma tumors by a single vaccination of CTL/T helper peptides in VacciMax. J Transl Med 2007, 5:20.
24. Schmittel A, Keilholz U, Scheibenbogen C: Evaluation of the interferongamma ELISPOT-assay for quantification of peptide specific T lymphocytes from peripheral blood. J Immunol Methods 1997, 210:167-174.
25. Overwijk WW, Theoret MR, Finkelstein SE, Surman DR, de Jong LA, Vyth-Dreese FA, Dellemijn TA, Antony PA, Spiess PJ, Palmer DC, Heimann DM, Klebanoff CA, Yu Z, Hwang LN, Feigenbaum L, Kruisbeek AM, Rosenberg SA, Restifo NP: Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J Exp Med 2003, 198:569-580.
26. Abbas AK, Lichtman AH: Basic Immunology: Functions and Disorders of the Immune System. Philadelphia: Elsevier Saunders; 2006.
27. Moon JJ, Suh H, Bershteyn A, Stephan MT, Liu H, Huang B, Sohail M, Luo S, Ho Um S, Khant H, Goodwin JT, Ramos J, Chiu W, Irvine DJ: Interbilayercrosslinked multilamellar vesicles as synthetic vaccines for potent humoral and cellular immune responses. Nat Mater 2011, 10:243-251.
28. Good NE, Winget GD, Winter W, Connolly TN, Izawa S, Singh RMM: Hydrogen ion buffers for biological research. Biochemistry 1966, 5:467-477.
29. Hermanson GT: Bioconjugate Techniques. Waltham: Academic Press; 2008.
30. Demers LM, Mirkin CA, Mucic RC, Reynolds RA, Letsinger RL, Elghanian R, Viswanadham G: A fluorescence-based method for determining the surface coverage and hybridization efficiency of thiol-capped oligonucleotides bound to gold thin films and nanoparticles. Anal Chem 2000, 72:5535-5541.
31. Qian X, Peng X-H, Ansari DO, Yin-Goen Q, Chen GZ, Shin DM, Yang L, Young AN, Wang MD, Nie S: In vivo tumor targeting and spectroscopic detection with surface-enhanced Raman nanoparticle tags. Nat Biotechnol 2008, 26:83-90.